Genmab A (GMAB) Total Current Liabilities (2023 - 2025)

Genmab A's Total Current Liabilities history spans 3 years, with the latest figure at $1.4 billion for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 91.8% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $1.4 billion, up 91.8%, while the annual FY2025 figure was $1.4 billion, 91.8% up from the prior year.
  • Total Current Liabilities reached $1.4 billion in Q4 2025 per GMAB's latest filing, up from $744.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $1.4 billion in Q4 2025 to a low of $368.0 million in Q4 2023.
  • Average Total Current Liabilities over 3 years is $846.3 million, with a median of $744.0 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: soared 102.17% in 2024, then skyrocketed 91.8% in 2025.
  • A 3-year view of Total Current Liabilities shows it stood at $368.0 million in 2023, then skyrocketed by 102.17% to $744.0 million in 2024, then surged by 91.8% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for GMAB's Total Current Liabilities are $1.4 billion (Q4 2025), $744.0 million (Q4 2024), and $368.0 million (Q4 2023).